Nonalcoholic Steatohepatitis (NASH) Market by Therapeutics | 2020
NASH Market is expected to garner $1.6 billion by 2020, registering a CAGR of 25.6% during the forecast period 2014-2020. Increase in cycles of clinical trials and their success rate has increased the probability of industries receiving commercial approval for NASH therapeutics by the end of 2017. NASH Market is expected to garner $1.6 billion by 2020, registering a CAGR of 25.6% during the forecast period 2014-2020. Increase in cycles of clinical trials and their success rate has increased the probability of industries receiving commercial approval for NASH therapeutics by the end of 2017.
from Abhi71
More from this publisher
13.06.2018
Views
Segments Nonalcoholic Steatohepatitis (NASH) Market
Segments Nonalcoholic Steatohepatitis (NASH) Market GFT505 Placebo Obeticholic Acid (INT- 747) Therapeutics Pioglitazo ne Simtuzumab and Liraglutide (Victoza) Vitamin E
- Page 1 and 2: Nonalcoholic Steatohepatitis (NASH)
- Page 3 and 4: Introductionof Nonalcoholic Steatoh
- Page 5: Table of Content (TOC) Chapter 1: I
- Page 9: Thank You Ceramic Matrix Composites
Segments<br />
<strong>Nonalcoholic</strong> <strong>Steatohepatitis</strong> (<strong>NASH</strong>) <strong>Market</strong>
Change language